Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2020-03-16 Regulatory Filings
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes an Item 2.02 "Results of Operations and Financial Condition" section, which mentions the announcement of financial results for the year ended December 31, 2019, but it states that the full text of the press release is furnished as an exhibit and that the information is not incorporated by reference into other filings. The document itself is 4449 characters, which is relatively short and primarily serves as an announcement of the financial results rather than containing the full detailed financial statements or analysis. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full annual report or detailed financial data itself.
2020-03-16 English
10-K
Annual Report FY 2019
2020-03-16 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 5, 2020, by Leap Therapeutics, Inc. The key content is under Item 5.07, which details the submission of matters to a vote of security holders at a Special Meeting. It provides the final voting results on proposals including an amendment to the certificate of incorporation and approval of private placement issuance. This matches the description of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is about official voting results from a shareholder meeting, not a full report or other type of filing. The document length is 4224 characters, which is consistent with a voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2020-03-09 English
4
Director's Dealing
2020-03-04 English
4
Director's Dealing
2020-03-04 English
4
Director's Dealing
2020-03-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.